Compound and composition for inducing neuroprotection
AssigneesRest Therapeutics, Universite De Montpellier, Institut National de la Sante et de la Recherche Medicale, Ecole Pratique Des Hautes Etudes
InventorsGilles Rubinstenn, Tangui Maurice
Life of this patent
Estimating the term…
Abstract
The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in inducing neuroprotection, in a subject in need thereof. The compound or a pharmaceutically acceptable salt thereof can be used in inducing neuroprotection in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology. The compound or a pharmaceutically acceptable salt thereof also can be used in preventing or treating a neurodegenerative pathology, and/or in preventing or decreasing cognitive impairment in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology.
Claims6
A method for inducing neuroprotection and treating excitotoxicity in a human subject diagnosed with a central nervous system pathology selected from the group consisting of tautopathies, synucleopathies, amyloidopathies, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, vascular dementia, Korsakoff's syndrome, alcohol withdrawal, ischaemia, head injury, and stroke, comprising:
- administering to the human subject orally at a dose of 10-100 mg per day of 3-(2-fluoroethyl) adamantan-1-amine (FENM) or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.